2017 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis C: WhatGraves’s New?
Kyung-Ah Kim
The Korean Journal of Gastroenterology · 2018
doi:10.4166/kjg.2018.71.6.315 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
With the advent of highly effective direct-acting antiviral agents (DAA), the treatment of hepatitis C virus infections continues to change. The Korean Association for the Study of the Liver updated guidelines for the management of hepatitis C were revised in 2015 in accordance with the introduction of new DAA into practice and a results of domestic and overseas research in late 2017. More effective and convenient DAAs are also recommended for each genotype depending on the presence of cirrhosis and treatment experience. DAA treatment in patients with chronic kidney disease is feasible. The treatment guidelines for DAA failure are also presented. The guidelines need to be revised constantly as new drugs are developed and the results of clinical research and experience accumulate.
Abstract licence: CC BY-NC
References10
10 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.